Evidence map›Paper›PMID 28876465›Full record

ArticleMolecular carcinogenesis2018

Procyanidin B2 3,3″-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK.

Rahul Kumar, Gagan Deep, Michael F Wempe, Joseph Surek, Amit Kumar, Rajesh Agarwal, Chapla Agarwal

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. AMPK's double-faced role in advanced stages of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  3. Review
  4. Frontiers in nutrition · 2021
    Article
  5. Article
  6. Article
  7. Procyanidin B2 3″-Biomolecules · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Rahul KumarDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Gagan DeepDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Michael F WempeDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Joseph SurekDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Amit KumarDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.
Chapla AgarwalDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Denver, Aurora, Colorado.ORCID http://orcid.org/0000-0003-1146-4890
University of Colorado Cancer Center · USUniversity of Colorado Denver · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Prostate Cancer Prevention by Procyanidins in Grape Seed ExtractR01CA091883 · NCI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, CHAPLA · 2003 to 2012
$3.3M
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.R01CA195708 · NCI · UNIVERSITY OF COLORADO DENVER · PI AGARWAL, RAJESH · 2014 to 2018
$2.2M
NCATS NIH HHS UL1 TR001082NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA091883NCI NIH HHS R01 CA195708
6 · The paper itself

Abstract

Neoplastic cells exhibit higher oxidative stress compared to normal cells; however, antioxidants based clinical trials have mostly failed. Another attractive therapeutic approach is to further increase the oxidative stress in cancer cells leading to cell death. Herein, we show that Procyanidin B2 3,3″-di-O-gallate (B2G2), the most active constituent of grape seed extract, treatment causes cell death in human prostate cancer (PCa) cells (LNCaP and 22Rv1) via increasing the reactive oxygen species (ROS) generation. Mechanistically, B2G2 treatment decreased the mitochondrial electron transport chain complex III activity leading to enhanced mitochondrial superoxide generation and decreased ATP production in LNCaP cells. Additional molecular studies revealed that B2G2-induced cell death was mediated mainly through ROS-induced sustained activation of ERK1/2, which was due to inhibition of MAP kinase phosphatase (MKP) activity as over-expression of MKP3 in LNCaP cells conferred significant protection against B2G2-induced cell death. Along with ERK1/2, AMP-activated protein kinase α (AMPKα) was also activated by B2G2 treatment, and pre-treatment with AMPKα inhibitor compound C significantly reversed the cytotoxic effects of B2G2 in LNCaP cells. Furthermore, pre-treatment of MKP3 over-expressing LNCaP cells with compound C further reduced the B2G2-induced cell death, suggesting the involvement of AMPKα along with MKP3 and ERK1/2 in the biological effects of B2G2. Together, these results for the first time identified that oxidative stress and MKP3 inhibition play a critical role in B2G2-induced cell death in PCa cells through sustained activation of both ERK1/2 and AMPKα. These results offer a unique opportunity to control this deadly malignancy through B2G2 use.

Indexed as

AMP-Activated Protein KinasesAnthocyaninsCell DeathCell Line, TumorCell SurvivalDual Specificity Phosphatase 6Enzyme ActivationHumansImmunoblottingMaleMitochondriaMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Oxidative StressProstatic NeoplasmsReactive Oxygen SpeciesAMP-Activated Protein KinasesAnthocyaninsDual Specificity Phosphatase 6MAPK1 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PRKAA1 protein, humanprocyanidin B2-3,3'-di-O-gallateReactive Oxygen SpeciesAMP-activated kinasedual-specificity phosphoprotein phosphataseextracellular-signal-regulated kinaseoxidative stressprocyanidin B2 3,3″-di-O-gallateprostate cancer

Identifiers

PMID28876465
PMCPMC5716889
OpenAlexW2753671067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.